Abstract：This paper made a detailed interpretation about the radiobiology-related contents in the ICRU report No.89, aiming to provide reference to resolve the problems related to radiobiology for the colleagues occupied in the brachytherapy for cervical cancer.
He Mingyuan,Tang Yuhuan,Zhao Hongfu et al. Interpretation of ICRU Report No.89(prescribing, recording, and reporting brachytherapy for cancer of the cervix)—radiobiology[J]. Chinese Journal of Radiation Oncology, 2019, 28(2): 140-145.
[1] Cleaves MA.Radium:With a preliminary note on radium rays in the treatment of cancer[J].Med Rec,1903,64(3):601-606.DOI:10.1016/j.brachy.2007.08.009. [2] Dose and volume specification for reporting intracavitary therapy in gynecology ICRU Report 38[M]. Bethesda:International commission on radiation units and measurements,1985:1-23. [3] Dose and Volume Specification for Reporting Interstitial Therapy ICRU Report 58[M].Bethesda:International commission on radiation units and measurements,1997:1-35. [4] Prescribing,recording,and reporting brachytherapy for cancer of the cervix ICRU report 89[M]. Bethesda:International commission on radiation units and measurements,2016:1-258. [5] Prescribing,recording and reporting photon beam therapy.report 50[M]. Bethesda:International commission on radiation units and measurements,1993:18-20. [6] Prescribing,recording and reporting photon beam therapy (supplement to report 50).report 62[M]. Bethesda:International commission on radiation units and measurements,1999:12-13. [7] Potter R,Haie-Meder C,Van Limbergen E,et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (Ⅱ):concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy radiation physics,radiobiology[J].Radiother Oncol,2006,78(1):67-77.DOI:10.1016/j.radonc.2005.11.014. [8] Kirisits C,Pötter R,Lang S,et al. Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer[J].Int J Radiat Oncol Biol Phys,2005,62(3):901-911.DOI:10.1016/j.ijrobp.2005.02.040. [9] Tanderup K,Fokdal L U,Sturdza A,et al. Effect of tumor dose,volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer[J].Radiother Oncol,2016,120(3):441-446.DOI:10.1016/j.radonc.2016.05.014. [10] De Brabandere M,Mousa AG,Nulens A,et al. Potential of dose optimisation in MRI-based PDR brachytherapy of cervix carcinoma[J].Radiother Oncol,2008,88(2):217-226.DOI:10.1016/j.radonc.2007.10.026. [11] Kogel AJVD.Radiobiological and clinical data on dose/volume effect relationships in normal tissues[J].Radiother Oncol,1993,29(2):127–128.DOI:10.1016/0167-8140(93)90237-233. [12] Dale R G,Coles IP,Deehan C,et al. Calculation of integrated biological response in brachytherapy[J].Int J Radiat Oncol Biol Phys,1997,38(3):633-642.DOI:10.1016/S0360-3016(97)00096-5. [13] Potter R,Georg P,Dimopoulos JC,et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer[J].Radiother Oncol,2011,100(1):116-123.DOI:10.1016/j.radonc.2011.07.012. [14] Logsdon MD,Eifel PJ.FIGO ⅢB squamous cell carcinoma of the cervix:an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy[J].Int J Radiati Oncol Biol Phys,1999,43(4):763-775.DOI:10.1016/S0360-3016(98)00482-9. [15] Georg P,Kirisits C,Goldner G,et al. Correlation of dose–volume parameters,endoscopic and clinical rectal side effects in cervix cancer patients treated with definitive radiotherapy including MRI-based brachytherapy[J].Radiother Oncol,2009,91(2):173-180.DOI:10.1016/j.radonc.2009.01.006. [16] Steel GG.The ESTRO Breur lecture. Cellular sensitivity to low dose-rate irradiation focuses the problem of tumour radioresistance[J].Radiother Oncol,1991,20(2):71-83. [17] Hall EJ.Radiation dose-rate:a factor of importance in radiobiology and radiotherapy[J].Br J Radiol,2014,45(530):81-97.DOI:10.1259/0007-1285-45-530-81. [18] Mazeron JJ,Simon JM,Le Pechoux C,et al. Effect of dose rate on local control and complications in definitive irradiation of T1-2 squamous cell carcinomas of mobile tongue and floor of mouth with interstitial iridium-192[J].Radiother Oncol,1991,21(1):39-47.DOI:10.1016/0167-8140(91)90339-I. [19] Patel FD,Negi PS,Sharma SC,et al. Dose rate correction in medium dose rate brachytherapy for carcinoma cervix[J].Radiother Oncol,1998,49(3):317-323.DOI:10.1016/S0167-8140(98)00100-5. [20] Newman G.Increased morbidity following the introduction of remote afterloading,with increased dose rate,for cancer of the cervix[J].Radiother Oncol,1996,39(2):97-103.DOI:10.1016/0167-8140(96)01721-5. [21] Wilkinson JM,Hendry JH,Hunter RD.Dose-rate considerations in the introduction of low-dose-rate afterloading intracavitary techniques for radiotherapy[J].Br J Radiol,1980,53(633):890-893.DOI:10.1259/0007-1285-53-633-890. [22] Paterson R.Studies in optimum dosage[J].Br J Radiol,1952,25(298):505-516.DOI:10.1259/0007-1285-25-298-505. [23] Lambin P,Gerbaulet A,Kramar A,et al. Phase Ⅲ trial comparing two low dose rates in brachytherapy of cervix carcinoma:report at two years[J].Int J Radiat Oncol Biol Phys,1993,25(3):405-412.DOI:10.1016/0360-3016(93)90060-9. [24] Jean-Jacques M,Jean-Marc S,Juanita,et al. Influence of dose rate on local control of breast carcinoma treated by external beam irradiation plus iridium 192 implant[J].Int J Radiat Oncol Biol Phys,1991,21(5):1173-1177.DOI:10.1016/0360-3016(91)90273-7. [25] Thames HD.An ‘Incomplete-repair’ Model for Survival after Fractionated and Continuous Irradiations[J].Int J Radiat Biol Relat Stud Phys Chem Med,1985,47(3):319-339.DOI:10.1080/09553008514550461. [26] Leborgne F,Fowler JF,Leborgne JH,et al. Medium-dose-rate brachytherapy of cancer of the cervix:preliminary results of a prospectively designed schedule based on the linear-quadratic model[J].Int J Radiat Oncol Biol Phys,1999,43(5):1061-1064.DOI:10.1016/S0360-3016(98)00527-6. [27] Arunkumar SB,Tomcha ST,Jaichand SL,et al. Biological effective doses in the intracavitary high dose rate brachytherapy of cervical cancer[J].J Contemp Brachyther,2011,3(4):188-192.DOI:10.5114/jcb.2011.26469. [28] Fowler JF.Dose reduction factors when increasing dose rate in LDR or MDR brachytherapy of carcinoma of the cervix[J].Radiother Oncol,1997,45(1):49-54.DOI:10.1016/S0167-8140(97)00072-8. [29] Fowler JF,Van Limbergen EF.Biological effect of pulsed dose rate brachytherapy with stepping sources if short half-times of repair are present in tissues[J].Int J Radiat Oncol Biol Phys,1997,37(4):877-883.DOI:10.1016/S0360-3016(96)00565-2. [30] Steel GG,Deacon JM,Duchesne GM,et al. The dose-rate effect in human tumor cells[J].Radiother Oncol,1987,9(4):299-310.DOI:10.1016/S0167-8140(87)80151-2. [31] Cox JD,Pajak TF,Marcial VA,et al. ASTRO plenary:interfraction interval is a major determinant of late effects,with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts:results from Radiation Therapy Oncology Group protocol 8313[J].Int J Radiat Oncol Biol Phys,1991,20(6):1191-1195.DOI:10.1016/0360-3016(91)90227-U. [32] Jeremic B,Milicic B,Dagovic A,et al. Interfraction interval in patients with stage Ⅲ non-small-cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy:final results in 536 patients[J].Am J Clin Oncol,2004,27(6):616-625.DOI:10.1097/01.coc.0000138964.98445.c4. [33] Liversage WE.The rate of decay of the dose equivalent of radiation induced sub-lethal damage[J].Cell Proliferation,2010,2(4):269-276.DOI:10.1111/j.1365-2184.1969.tb00236.x. [34] Thames HD.An′incomplete-repair′ model for survival after fractionated and continuous irradiations[J].Int J Radiat Oncol Biol Phys,1985,47(3):319-339.DOI:10.1080/09553008514550461. [35] Weber DC,Kurtz JM,Allal AS.The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy.[J].Int J Radiat Oncol Biol Phys,2001,50(3):675-680.DOI:10.1016/S0360-3016(01)01510-3. [36] Bentzen SM,Thames HD.Clinical evidence for tumor clonogen regeneration:interpretations of the data[J].Radiother Oncol,1991,22(3):161-166.DOI:10.1016/0167-8140(91)90019-D. [37] Dubray B,Mazeron JJ,Simon JM,et al. Time factors in breast carcinoma:influence of delay between external irradiation and brachytherapy[J].Radiother Oncol,1992,25(4):267-272.DOI:10.1016/0167-8140(92)90246-Q. [38] Pernot M,Malissard L,Hoffstetter S,et al. Influence of tumoral,radiobiological,and general factors on local control and survival of a series of 361 tumors of the velotonsillar area treated by exclusive irradiation (external beam irradiation+brachytherapy or brachytherapy alone)[J].Int J Radiat Oncol Biol Phys,1994,30(5):1051-1507.DOI:10.1016/0360-3016(94)90309-3. [39] Mazeron R,Castelnau-Marchand P,Dumas I,et al. Impact of treatment time and dose escalation on local control in locally advanced cervical cancer treated by chemoradiation and image-guided pulsed-dose rate adaptive brachytherapy[J].Radiother Oncol,2015,114(2):257-263.DOI:10.1016/j.radonc.2014.11.045. [40] Chen SW,Liang JA,Yang SN,et al. The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy[J].Radiother Oncol,2003, 67(1):69-76.DOI:10.1016/S0167-8140(02)00439-5. [41] Pötter R,Tanderup K,Kirisits C,et al. The EMBRACE Ⅱ study:The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies[J].Clin Transl Radiat Oncol,2018,9(C):48.DOI:10.1016/j.ctro.2018.01.001. [42] Ling CC,Spiro IJ,Mitchell J,et al. The variation of OER with dose rate[J].Int J Radiat Oncol Biol Phys,1985,11(7):1367-1373.DOI:10.1016/0360-3016(85)90253-6. [43] Berg APVD,Geel CAJFV,Hooije CMCV.Tumor hypoxia—a confounding or exploitable factor in interstitial brachytherapy? Effects of tissue trauma in an experimental rat tumor model[J].Int J Radiat Oncol Biol Phys,2000,48(1):233-240.DOI:10.1016/S0360-3016(00)00599-X. [44] Baumann M,Dörr W,Petersen C,et al.repopulation during fractionated radiotherapy:much has been learned,even more is open[J].Int J Radiat Biol 2003,79(7):465-467.DOI:10.1080/0955300031000160259. [45] Videtic GM,Stephans KL,Woody NM,et al.30 Gy or 34 Gy? Comparing 2 single-fraction SBRT dose schedules for stage Ⅰ medically inoperable non-small cell lung cancer[J].Int J Radiat Oncol Biol Phys,2014,90(1):203-208.DOI:10.1016/j.ijrobp.2014.05.017. [46] Prescribing,recording and reporting photon-beam intensity-modulated radiation therapy (IMRT) report 83[M].Bethesda:International commission on radiation units and measurements,2010:30-33. [47] Cohen L.Radiotherapy in breast cancer. I.The dose-time relationship theoretical considerations[J].Br J Radiol,1952,25(300):636-642.DOI:10.1259/0007-1285-25-300-636. [48] Lee WR.Extreme hypofractionation for prostate cancer[J].Expert Rev Anticanc,2009,9(1):61-65.DOI:10.1586/14737140.9.1.61. [49] Bentzen SM,Dorr W,Gahbauer R,et al. Bioeffect modeling and equieffective dose concepts in radiation oncology—terminology,quantities and units[J].Radiother Oncol,2012, 105(2):266-268.DOI:10.1016/j.radonc.2012.10.006. [50] Van de Kamer JB., De Leeuw AA,Moerland MA,et al. Determining DVH parameters for combined external beam and brachytherapy treatment:3D biological dose adding for patients with cervical cancer[J].Radiother Oncol,2010,94(2):248-253.DOI:10.1016/j.radonc.2009.12.011. [51] Fenkell L,Assenholt M,Nielsen SK,et al. Parametrial boost using midline shielding results in an unpredictable dose to tumor and organs at risk in combined external beam radiotherapy and brachytherapy for locally advanced cervical cancer[J].Int J Radiat Oncol Biol Phys,2011,79(5):1572-1579.DOI:10.1016/j.ijrobp.2010.05.031. [52] Kirkpatrick JP,Brenner DJ,Orton CG.The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery[J].Med Phys,2009,36(8):3381-3384.DOI:10.1118/1.3157095.
2019, Vol. 28 
